为进一步确保重点品种双蚁复方感冒灵颗粒核心原材料野菊花质量稳定，同时学习和引进湖北金鹰的野 菊花标准化种植技术，12月21日，广西双蚁药业有限公司董事长王波、副总经理陈才安一行赴湖北金鹰 农业发展有限公司，就野菊花良种繁育、规模化种植及加工等全产业链环节展开实地考察调研，为双方 后续深度合作奠定坚实基础。 考察期间，王波董事长一行先后深入湖北金鹰农业野菊花良种繁育中心、标准化种植基地及现代化加工 厂房，通过现场观摩、交流问询等方式，详细了解野菊花种质资源圃运营、良种选育技术攻关、规模化 种植管理模式及产地加工全流程。湖北金鹰农业先进的生产设备、完善的产业链布局和严格的质量控制 体系，给考察团留下深刻印象，得到了高度赞叹。 湖北金鹰农业发展有限公司作为湖北省农业产业化省级重点龙头企业，拥有2580亩道地中药材种植基 地，其中野菊花种植规模达1030亩，还建有20亩野菊花种质资源圃、100亩种源基地及200亩种苗基地， 其种源基地采收的种子可供应全国数万亩野菊花种植；同时在湖北多县市推广种植野菊花超5万亩，形 成了集科研、育苗、种植、加工、销售于一体的完整产业链。此外，公司多年来深耕中药材产业，与华 润三九（00 ...

新华财经南昌12月12日电（记者张新新崔璐）近两年来，我国中药材市场价格经历了一轮暴涨暴跌，走 势犹如"过山车"。记者在甘肃、安徽、江西等多地调研发现，虽然中药材价格正常波动属于市场常态， 但部分品种在短期内出现极端涨跌，已超出合理范围，不仅扰乱产业链稳定运行，也最终损害了药农、 企业和患者的利益。相关人士建议，应加强价格监测与市场监管，并通过科学规划种植、提升产业组织 化水平等措施，推动中药材行业迈向稳健发展。 价格骤变留下"产业伤痕" "今年猫爪草的价格波动相当夸张。"江西省樟树市的药材商熊伏明告诉记者，平时每公斤70至80元， 2023年初开始涨，今年3月一度冲到1100元，现在却只剩46元。这种外形似猫爪、用于化痰散结的药 材，在三年内上演了"过山车"行情。 在甘肃等主产区，黄芪、党参、当归、甘草等大宗药材价格也普遍下行。甘肃成源堂药业负责人周江辉 表示，当地主流药材价格同比平均下跌约40%，例如党参从每公斤120元跌至50元左右，黄芪鲜货价格 也从每公斤7元多降至4.5元上下。 康美·中国中药材价格总指数显示，自2024年7月以来，中药材价格持续走低。而在本轮下跌前，中药材 价格曾保持较长时间高位运 ...

Core Viewpoint - Yunnan Baiyao announced the acquisition of 100% equity in Juyatang Pharmaceutical Co., Ltd. for a total consideration of 660 million yuan to enhance the development of the traditional Chinese medicine industry in Yunnan Province and expand its business nationwide [1] Group 1: Acquisition Details - The acquisition is aimed at responding to the Yunnan provincial government's call for high-quality development in the traditional Chinese medicine industry [1] - The total consideration for the acquisition is 660 million yuan [1] - Juyatang specializes in the production and sales of traditional Chinese medicine pieces, toxic traditional Chinese medicine pieces, directly consumable traditional Chinese medicine pieces, and formula granules [1] Group 2: Strategic Objectives - The acquisition aligns with the company's strategic development goals to boost the sales of traditional Chinese medicine within Yunnan Province [1] - The move is expected to facilitate the nationwide expansion of Yunnan Baiyao's related business operations [1] - The company aims to enhance the collaborative efficiency of the traditional Chinese medicine industry chain through this acquisition [1]

Group 1 - The company announced that its wholly-owned subsidiary, Yunnan Baiyao Group Traditional Chinese Medicine Resources Co., Ltd., plans to acquire 100% equity of An Guo Shi Ju Yao Tang Pharmaceutical Co., Ltd. for 660 million yuan in cash [1] - The acquisition aims to respond to the high-quality development requirements of the traditional Chinese medicine industry in Yunnan Province and align with the company's strategic development goals [1] - The acquisition is expected to enhance the sales of traditional Chinese medicine materials within Yunnan Province, accelerate the national business layout of Yunnan Baiyao, achieve scale expansion, and improve the collaborative efficiency of the traditional Chinese medicine industry chain [1] Group 2 - Ju Yao Tang specializes in the production and sales of traditional Chinese medicine pieces, toxic traditional Chinese medicine pieces, directly consumable traditional Chinese medicine pieces, and formula granules, demonstrating stable and sustainable profitability [1]